Aplastic anemia: Difference between revisions
imported>Michael Benjamin No edit summary |
imported>Matt Mahlmann (added categories) |
||
| Line 33: | Line 33: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:CZ Live]] | |||
[[Category:Health Sciences Workgroup]] | |||
Revision as of 20:53, 8 April 2007
Aplastic anemia is clinical syndrome, characterized by a hypoplastic bone marrow in the setting of pancytopenia. The pathogenesis of aplastic anemia is damage to the pluripotent stem cell reserves of the bone marrow, which leads to profound low white blood cell, red blood cell, and platelet counts.
Patterns of aplastic anemia include:
- Hereditary
- Drug-induced
- Radiation
- Infection
- Idiopathic
Hereditary forms of aplastic anemia
Fanconi's anemia is the most common hereditary aplastic anemia. Genes involved in DNA mismatch repair have been implicated in Fanconi's anemia, and aplastic anemia usually takes place before adulthood.
Drugs and aplastic anemia
Drugs commonly reported to cause aplastic anemia are not routinely used in clinical practice today. Some of these include:
- Phenylbutazone
- Chloramphenicol
- Gold
- Sulfonamides
- Sulfonylureas, such as glipizide
- Felbamate
- Carbamazepine
- Valproic acid
- Phenytoin
- Nifedipine
- Ticlopidine [1]
- Clopidogrel [2]
- Penicillin
- Allopurinol
- Furosemide
Radiation-induced aplastic anemia
A single exposure to 5 Gy of radiation energy will kill 50 percent of recipients, due to irreversible injury to hematopoeitic stem cells.
Infection-induced aplastic anemia
Idiopathic aplastic anemia
Treatment
References
- ↑ Symeonidis A, Kouraklis-Symeonidis A, Seimeni U, Galani A, Giannakoulas N, Fragopanagou E, Tiniakou M, Matsouka P, Zoumbos N (2002). "Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases". Am J Hematol 71 (1): 24-32. PMID 12221670.
- ↑ Meyer B, Staudinger T, Lechner K (2001). "Clopidogrel and aplastic anaemia". Lancet 357 (9266): 1446-7. PMID 11360950.